Hydrogel-protein conjugates and uses thereof

A crosslinked hydrogel matrix with Fc-binding ligands addresses the challenge of localized and prolonged IgG-based drug delivery, enhancing efficacy and reducing adverse effects through controlled release.

WO2026143102A1PCT designated stage Publication Date: 2026-07-02UNIV OF MIAMI
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
UNIV OF MIAMI
Filing Date
2025-12-23
Publication Date
2026-07-02

AI Technical Summary

Technical Problem

Existing methods for delivering IgG-based biologic drugs face challenges in achieving localized and prolonged delivery without systemic distribution, leading to adverse effects and inefficiencies, and current hydrogel systems suffer from burst release and incomplete drug delivery.

Method used

A composition of a therapeutic protein conjugated to a crosslinked hydrogel matrix via an Fc-binding ligand, utilizing a crosslinked hydrophilic polymer with specific reactive groups for controlled drug release, allowing for localized and sustained delivery.

Benefits of technology

The solution enables site-specific, prolonged delivery of therapeutic proteins with controlled release characteristics, reducing adverse effects and improving drug efficacy by targeting specific locations within the body.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2025061108_02072026_PF_FP_ABST
    Figure US2025061108_02072026_PF_FP_ABST
Patent Text Reader

Abstract

Compositions including a multi-armed hydrophilic polymer hydrogel conjugated to a therapeutic Fc-containing protein, such as an antibody, via an Fc-binding ligand, and processes for preparing the compositions comprising crosslinking a mixture comprising the multi-armed hydrophilic polymer and a crosslinker are disclosed.
Need to check novelty before this filing date? Find Prior Art